- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02336724
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic gastrointestinal stromal tumor who failed from imatinib therapy.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing Bayi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Unresectable advanced or metastatic, histologically-confirmed, gastrointestinal stromal tumor.Patients has been failed from last imatinib treatment due to disease progression or unacceptable toxicity and unable to use sunitinib.
- At least 2 weeks since the last imatinib administration
- Must have at least one measurable disease by RECIST1.1 criteria(tumour lesions ≥10mm in longest diameter, malignant lymph nodes ≥15mm in short axis, scanning layer ≤ 5 mm).
- ECOG Performance status 0-1
- Participants have adequate organ and marrow function as defined below:
neutrophils ≥ 1.5×10^9/L, platelets≥ 80×10^9/L, hemoglobin≥ 90g/L (no blood transfusion within 14 days), serum transaminase(ALT and AST ) ≤ 2.5×ULN (If liver metastases are present, serum transaminase≤5×ULN), total bilirubin ≤ 1.25×ULN, cholesterol ≤ 7.75mmol/L and triglyceride≤1 x ULN, creatinine ≤1x ULN,creatinine clearance rate > 50ml/min Urine protein ≥ + + and confirmed the 24-hour urinary protein>1.0 g normal serum calcium, potassium,magnesium, phosphorus INR≤1.5 and APTT≤1.5 ULN LVEF: ≥ 50%
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Prior therapy with tyrosine kinase -inhibitor agent targeting at VEGFR, PDGFR and c-Kit
- The toxicity from previous imatinib or other treatment has not been recovered ≤ grade 1 according to CTCAE 3.0
- Have surgery or radiotherapy within 4 weeks or have temporary radiotherapy for palliative treatment within 2 weeks
- A variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction)
- Other cancer diagnosed within past 5 years or currently suffering , but other than cure basal cell carcinoma and cervical carcinoma in situ
- Within 12 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc
- Uncontrollable thyroid dysfunction, even using medical therapy
- Preexisting arrhythmia (including QT interval ≥ 450ms for male and 470ms for female) and ≥ grade I heart failure
- Patients with uncontrollable hypertension after using single agent therapy (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg).
- Known acute or chronic active hepatitis
- Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital immunodeficiency, or organ transplantation
- Less than 4 weeks from the last clinical trial
- Child bearing or pregnancy female. Potential child bearing female must have a negative urine or serum pregnancy test result before initiating.
- All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 6 months after the last dose of test drug.
- Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
- Mental disorders history, or Psychotropic drug abuse history
- Abuse of Psychiatric drugs or dysphrenia
- Other reasons from investigators' judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Famitinib
25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease Control Rate
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival
Time Frame: 24 months
|
24 months
|
Objective Response Rate
Time Frame: 12 weeks
|
12 weeks
|
Overall survival
Time Frame: 96 months
|
96 months
|
Incidence of adverse events
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMTN-II-GIST
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Stromal Tumor
-
Hospital Universitario Virgen de la ArrixacaNot yet recruitingLiver Diseases | Liver Transplantation | Liver Neoplasms | Gastrointestinal Stromal Tumors | Metastasis | Liver Metastases | Liver Transplant; Complications | Liver Cancer | Liver Transplant Disorder | Liver Carcinoma | GIST, Malignant | GIST | Metastases | Metastatic Liver Cancer | Gastrointestinal Stromal Tumor of... and other conditionsSpain
-
Centre Leon BerardRecruitingMetastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)France
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Gastrointestinal Stromal Tumor | Metastatic Sarcoma | Locally Advanced Sarcoma | Locally Advanced Gastrointestinal Stromal Tumor | Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal... and other conditionsUnited States
-
Centre Leon BerardRecruitingC-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)France
-
Ascentage Pharma Group Inc.HealthQuest Pharma Inc.RecruitingSolid Tumor, Adult | Gastrointestinal Stromal Tumor (GIST)China
-
ARCAGY/ GINECO GROUPRoche Pharma AGCompleted
-
Assaf-Harofeh Medical CenterUnknownSoft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
-
AB ScienceCompletedGastro Intestinal Stromal TumorFrance
-
Institut BergoniéFrench Sarcoma GroupRecruitingGastro Intestinal Stromal TumorFrance
-
University Medical Center GroningenDutch Cancer SocietyRecruitingGastro-intestinal Stromal TumorNetherlands
Clinical Trials on Famitinib
-
Jiangsu HengRui Medicine Co., Ltd.CompletedColorectal Cancer Metastatic | Colorectal Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen University; Shanghai Pulmonary Hospital, Shanghai, ChinaSuspendedNon-Small Cell Lung Cancer (NSCLC)China
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRenal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer RecurrentChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Sun Yat-sen UniversityCompletedRecurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal CarcinomaChina
-
Shanghai Chest HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruitingHealthy SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesTerminatedGastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting